Vioxx Fallout: FDA, DTC Ads Take It On The Chin In Journal Editorials
This article was originally published in The Tan Sheet
Executive Summary
Merck's withdrawal of Vioxx (rofecoxib) from the market may have repercussions on direct-to-consumer advertising for both Rx and OTC non-steroidal anti-inflammatory drugs